Suppr超能文献

含3-(哌啶-4-基甲氧基)吡啶的化合物是赖氨酸特异性去甲基化酶1的强效抑制剂。

3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.

作者信息

Wu Fangrui, Zhou Chao, Yao Yuan, Wei Liping, Feng Zizhen, Deng Lisheng, Song Yongcheng

机构信息

Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.

Dan L. Duncan Cancer Center, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.

出版信息

J Med Chem. 2016 Jan 14;59(1):253-263. doi: 10.1021/acs.jmedchem.5b01361. Epub 2015 Dec 24.

Abstract

Methylation of histone lysine residues plays important roles in gene expression regulation as well as cancer initiation. Lysine specific demethylase 1 (LSD1) is responsible for maintaining balanced methylation levels at histone H3 lysine 4 (H3K4). LSD1 is a drug target for certain cancers, due to important functions of methylated H3K4 or LSD1 overexpression. We report the design, synthesis, and structure-activity relationships of 3-(piperidin-4-ylmethoxy)pyridine containing compounds as potent LSD1 inhibitors with Ki values as low as 29 nM. These compounds exhibited high selectivity (>160×) against related monoamine oxidase A and B. Enzyme kinetics and docking studies suggested they are competitive inhibitors against a dimethylated H3K4 substrate and provided a possible binding mode. The potent LSD1 inhibitors can increase cellular H3K4 methylation and strongly inhibit proliferation of several leukemia and solid tumor cells with EC50 values as low as 280 nM, while they had negligible effects on normal cells.

摘要

组蛋白赖氨酸残基的甲基化在基因表达调控以及癌症发生过程中发挥着重要作用。赖氨酸特异性去甲基化酶1(LSD1)负责维持组蛋白H3赖氨酸4(H3K4)的甲基化水平平衡。由于甲基化H3K4的重要功能或LSD1的过表达,LSD1是某些癌症的药物靶点。我们报道了含3-(哌啶-4-基甲氧基)吡啶化合物作为强效LSD1抑制剂的设计、合成及构效关系,其Ki值低至29 nM。这些化合物对相关的单胺氧化酶A和B表现出高选择性(>160倍)。酶动力学和对接研究表明它们是针对二甲基化H3K4底物的竞争性抑制剂,并提供了一种可能的结合模式。强效LSD1抑制剂可增加细胞H3K4甲基化,并强烈抑制几种白血病和实体瘤细胞的增殖,EC50值低至280 nM,而对正常细胞的影响可忽略不计。

相似文献

1
3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.
J Med Chem. 2016 Jan 14;59(1):253-263. doi: 10.1021/acs.jmedchem.5b01361. Epub 2015 Dec 24.
2
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
J Hematol Oncol. 2016 Mar 12;9:24. doi: 10.1186/s13045-016-0252-7.
3
Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Bioorg Chem. 2018 Aug;78:7-16. doi: 10.1016/j.bioorg.2018.02.016. Epub 2018 Feb 16.
5
Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
PLoS One. 2017 Feb 3;12(2):e0170301. doi: 10.1371/journal.pone.0170301. eCollection 2017.
6
[1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
Eur J Med Chem. 2020 Feb 1;187:111989. doi: 10.1016/j.ejmech.2019.111989. Epub 2019 Dec 20.
7
Identification of cell-active lysine specific demethylase 1-selective inhibitors.
J Am Chem Soc. 2009 Dec 9;131(48):17536-7. doi: 10.1021/ja907055q.
8
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Eur J Med Chem. 2017 Nov 10;140:392-402. doi: 10.1016/j.ejmech.2017.09.038. Epub 2017 Sep 21.
10
Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
J Biomol Struct Dyn. 2019 Oct;37(16):4200-4214. doi: 10.1080/07391102.2018.1538903. Epub 2018 Dec 5.

引用本文的文献

3
The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities.
Genes Dis. 2023 Mar 23;11(2):645-663. doi: 10.1016/j.gendis.2022.12.020. eCollection 2024 Mar.
4
LSD1-Based Reversible Inhibitors Virtual Screening and Binding Mechanism Computational Study.
Molecules. 2023 Jul 10;28(14):5315. doi: 10.3390/molecules28145315.
5
Quinazolinone Compounds Have Potent Antiviral Activity against Zika and Dengue Virus.
J Med Chem. 2023 Aug 10;66(15):10746-10760. doi: 10.1021/acs.jmedchem.3c00924. Epub 2023 Jul 28.
6
LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials.
Front Pharmacol. 2023 Feb 2;14:1120911. doi: 10.3389/fphar.2023.1120911. eCollection 2023.
8
Carrier-free supramolecular nanoassemblies of pure LSD1 inhibitor for effective anti-tumor therapy.
Front Chem. 2022 Sep 30;10:1012882. doi: 10.3389/fchem.2022.1012882. eCollection 2022.

本文引用的文献

1
5
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.
Nat Rev Drug Discov. 2014 Sep;13(9):673-91. doi: 10.1038/nrd4360. Epub 2014 Aug 18.
6
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
PLoS One. 2014 May 23;9(5):e98270. doi: 10.1371/journal.pone.0098270. eCollection 2014.
7
A selective phenelzine analogue inhibitor of histone demethylase LSD1.
ACS Chem Biol. 2014 Jun 20;9(6):1284-93. doi: 10.1021/cb500018s. Epub 2014 Apr 7.
10
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Blood. 2013 Aug 8;122(6):1017-25. doi: 10.1182/blood-2013-04-497644. Epub 2013 Jun 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验